Alexander K Glaros
Overview
Explore the profile of Alexander K Glaros including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
33
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Idowu M, Otieno L, Dumitriu B, Lobo C, Thein S, Andemariam B, et al.
Lancet Haematol
. 2024 Dec;
12(1):e35-e44.
PMID: 39644907
Background: Sickle cell disease, a debilitating, inherited haemolytic anaemia with premature morbidity and mortality, affects millions globally. Mitapivat, a first-in-class, oral, allosteric activator of pyruvate kinase, improves red blood cell...
2.
Glaros A, Callaghan M, Smith W, Zaidi A
EJHaem
. 2022 Sep;
3(3):653-659.
PMID: 36051054
Evidence suggests neuropathic pain (NP) develops over time in sickle cell disease (SCD), contributing to a complex, difficult-to-treat phenotype, with management based on scant evidence. One characteristic of NP found...
3.
Peine B, Callaghan M, Callaghan J, Glaros A
J Clin Med
. 2022 Jun;
11(12).
PMID: 35743561
Sickle cell disease (SCD) increases the incidence of childhood stroke eighty-fold. Stroke risk can be estimated by measurement of the blood velocity through the middle cerebral artery (MCA) using transcranial...
4.
Zaidi A, Glaros A, Lee S, Wang T, Bhojwani R, Morris E, et al.
Orphanet J Rare Dis
. 2021 Nov;
16(1):460.
PMID: 34727959
Background And Purpose: Sickle cell disease (SCD) is a collection of rare inherited blood disorders affecting approximately 100,000 people in the U.S. and 20-25 million people globally. Individuals with SCD...
5.
Glaros A, Razvi R, Shah N, Zaidi A
Ther Adv Hematol
. 2021 Apr;
12:20406207211001136.
PMID: 33796238
Sickle cell disease, despite its recognition as a severely debilitating genetic condition affecting hundreds of thousands of neonates throughout the world each year, was not a target of pharmaceutical research...
6.
Zaidi A, Glaros A, Weyand A
Blood Adv
. 2021 Feb;
5(1):277-278.
PMID: 33570648
No abstract available.